PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
June 1, 2024Journal of Clinical Oncology

KRAS mutation subtypes responded differently to combination immunotherapy via disturbing myeloid-derived suppressor cells in non-small cell lung cancer.

View Full Paper
Ask AI
Bookmark
Share

Authors

CGCaifeng GongXYXu YangJZJinsong Zhang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gong et al. (2024) studied this question.

synapsesocial.com/papers/68e672e0b6db6435875fd69chttps://doi.org/10.1200/jco.2024.42.16_suppl.8635
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1KRAS G12C Mutation Predicts Improved Survival in NSCLC Patients Receiving Immunotherapy: Insights from a Real-World Cohort2025 · 3 citations
  2. 257P Retrospective comparative analysis of KRAS mutations in mNSCLC patients treated with first-line immunotherapy or chemoimmunotherapy2024
  3. 355P Differences in response to immune treatment between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer2024 · 1 citations
  4. 4KRAS mutation subtypes in metastatic non-small cell lung cancer2025 · 2 citations
  5. 5Clinicopathological Characteristics and Prognostic Impact of KRAS Mutations in Non-Small Cell Lung Cancer2026